全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Kusma Pyakurel , Salome V Ibba ...
来源:[J].Journal of Translational Medicine(IF 3.459), 2015, Vol.13 (1)Springer
摘要:Abstract(#br) Background(#br)An important portion of asthmatics do not respond to current therapies. Thus, the need for new therapeutic drugs is urgent. We have demonstrated a critical role for PARP in experimental asthma. Olaparib, a PARP inhibitor, was recently introduced ...
作者:Kusma Pyakurel , Matthew R. Lammi ...
来源:[J].Mediators of Inflammation(IF 3.882), 2016, Vol.2016Hindawi
摘要:Although expression of inducible NO synthase (iNOS) in the lungs of asthmatics and associated nitrosative damage are established, iNOS failed as a therapeutic target for blocking airway hyperresponsiveness (AHR) and inflammation in asthmatics. This dichotomy calls for better stra...
作者:Kusma Pyakurel , Jihang Ju ...
来源:[J].The Journal of Allergy and Clinical Immunology(IF 12.047), 2015, Vol.135 (2), pp.425-440Elsevier
摘要:Background(#br)We reported that DNA-dependent protein kinase (DNA-PK) is critical for the expression of nuclear factor κB–dependent genes in TNF-α–treated glioblastoma cells, suggesting an involvement in inflammatory diseases.(#br)Objective(#br)We sought to investigate ...
作者:Kusma Pyakurel , Abdelmetalab Tarhuni ...
来源:[J].Circulation(IF 15.202), 2016, Vol.134 (Suppl_1 Su), pp.A20249-A20249Wolters Kluwer
摘要:Introduction: Microparticles (MPs) are submicron vesicles released from cells both in health and in response to inflammation, apoptosis, or shear stress. Prior investigations have suggested that MPs may play an active role in endothelial dysfunction through paracrine signali...
作者:Kusma Pyakurel , Salome V. Ibba ...
来源:[J].Clinical Science, 2015, Vol.129 (11), pp.951-962Duke University Press
摘要:The present study establishes poly(ADP-ribose)polymerase's (PARP's) role in chronic asthma, demonstrates that it is activated in human asthma, increases the clinical relevance of targeting PARP for blocking or preventing chronic asthma in humans and presents olaparib as a li...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×